Evidence map›Paper›PMID 37460534›Full record

ArticleCell death & disease2023

NEDD8-activating enzyme inhibition potentiates the anti-myeloma activity of natural killer cells.

Sara Petillo, Elena Sproviero, Luisa Loconte, Lorenzo Cuollo, Alessandra Zingoni, Rosa Molfetta, Cinzia Fionda, Alessandra Soriani, Cristina Cerboni, Maria Teresa Petrucci and 4 more

Open access · goldAbstract read
In one paragraph

Article in Cell death & disease, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Article
  10. Review
  11. Review
  12. Article
  13. Review
  14. Oncolytic virus and inhibitor for NEDD8-activating enzyme pevonedistat: Promising combination for cancer therapy?Molecular therapy : the journal of the American Society of Gene Therapy · 2023
    Article
  15. Neddylation Regulation of Immune Responses.Research (Washington, D.C.) · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 2 institutions in 1 country.

Sara PetilloDepartment of Molecular Medicine, Sapienza University of Rome, Rome, Italy.
Elena SprovieroDepartment of Molecular Medicine, Sapienza University of Rome, Rome, Italy.
Luisa LoconteDepartment of Molecular Medicine, Sapienza University of Rome, Rome, Italy.
Lorenzo CuolloDepartment of Molecular Medicine, Sapienza University of Rome, Rome, Italy.
Alessandra ZingoniDepartment of Molecular Medicine, Sapienza University of Rome, Rome, Italy.
Rosa MolfettaDepartment of Molecular Medicine, Sapienza University of Rome, Rome, Italy.ORCID 0000-0003-2904-6371
Cinzia FiondaDepartment of Molecular Medicine, Sapienza University of Rome, Rome, Italy.
Alessandra SorianiDepartment of Molecular Medicine, Sapienza University of Rome, Rome, Italy.ORCID 0000-0001-5461-9026
Cristina CerboniDepartment of Molecular Medicine, Sapienza University of Rome, Rome, Italy.
Maria Teresa PetrucciHematology, Department of Translational and Precision Medicine, Sapienza University of Rome, Rome, Italy.
Francesca FazioHematology, Department of Translational and Precision Medicine, Sapienza University of Rome, Rome, Italy.
Rossella PaoliniDepartment of Molecular Medicine, Sapienza University of Rome, Rome, Italy.ORCID 0000-0001-7605-1531
Angela SantoniDepartment of Molecular Medicine, Sapienza University of Rome, Rome, Italy.
Marco CippitelliDepartment of Molecular Medicine, Sapienza University of Rome, Rome, Italy. marco.cippitelli@uniroma1.it.ORCID 0000-0002-9620-538X
Sapienza University of Rome · ITIstituto Neurologico Mediterraneo · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Natural Killer (NK) cells act as important regulators in the development and progression of hematological malignancies and their suppressor activity against Multiple Myeloma (MM) cells has been confirmed in many studies. Significant changes in the distribution of NK cell subsets and dysfunctions of NK cell effector activities were described in MM patients and correlated with disease staging. Thus, restoring or enhancing the functionality of these effectors for the treatment of MM represents a critical need. Neddylation is a post-translational modification that adds a ubiquitin-like molecule, NEDD8, to the substrate protein. One of the outcomes is the activation of the Cullin Ring Ligases (CRLs), a class of ubiquitin-ligases that controls the degradation of about 20% of proteasome-regulated proteins. Overactivation of CRLs has been described in cancer and can lead to tumor growth and progression. Thus, targeting neddylation represents an attractive approach for cancer treatment. Our group has recently described how pharmacologic inhibition of neddylation increases the expression of the NKG2D activating receptor ligands, MICA and MICB, in MM cells, making these cells more susceptible to NK cell degranulation and killing. Here, we extended our investigation to the direct role of neddylation on NK cell effector functions exerted against MM. We observed that inhibition of neddylation enhanced NK cell-mediated degranulation and killing against MM cells and improved Daratumumab/Elotuzumab-mediated response. Mechanistically, inhibition of neddylation increased the expression of Rac1 and RhoA GTPases in NK cells, critical mediators for an efficient degranulation at the immunological synapse of cytotoxic lymphocytes, and augmented the levels of F-actin and perforin polarization in NK cells contacting target cells. Moreover, inhibition of neddylation partially abrogated TGFβ-mediated repression of NK cell effector activity. This study describes the role of neddylation on NK cell effector functions and highlights the positive immunomodulatory effects achieved by the inhibition of this pathway in MM.

Indexed as

Antineoplastic AgentsMultiple MyelomaHumansKiller Cells, NaturalLigasesNEDD8 ProteinProteinsAntineoplastic AgentsLigasesNEDD8 ProteinNEDD8 protein, humanProteins

Identifiers

PMID37460534
PMCPMC10352239
OpenAlexW4384523661

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.